Newron Receives Positive Opinion for Orphan Medicinal Product Designation for Sarizotan to Treat Patients with Rett Syndrome from the Committee for Orphan Medicinal Products from the European Medicines Agency

14:12 25.06.2015
PRESS RELEASE: Newron Pharmaceuticals S.p.A. ("Newron"), a research and development company focused on novel CNS and pain therapies, announces that it has received a positive opinion for its New Chemical Entity Sarizotan for the treatment of Rett Syndrome......